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Abstract
Introduction: The performance of N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-reactive protein
(CRP) to predict clinical outcomes in ICU patients is unimpressive. We aimed to assess the prognostic value of NT-
proBNP, CRP or the combination of both in unselected medical ICU patients.
Methods: A total of 576 consecutive patients were screened for eligibility and followed up during the ICU stay. We
collected each patient’s baseline characteristics including the Acute Physiology and Chronic Health Evaluation II
(APACHE-II) score, NT-proBNP and CRP levels. The primary outcome was ICU mortality. Potential predictors were
analyzed for possible association with outcomes. We also evaluated the ability of NT-proBNP and CRP additive to
APACHE-II score to predict ICU mortality by calculation of C-index, net reclassification improvement (NRI) and
integrated discrimination improvement (IDI) indices.
Results: Multiple regression revealed that CRP, NT-proBNP, APACHE-II score and fasting plasma glucose
independently predicted ICU mortality (all P < 0.01). The C-index with respect to prediction of ICU mortality of
APACHE II score (0.82 ± 0.02; P < 0.01) was greater than that of NT-proBNP (0.71 ± 0.03; P < 0.01) or CRP (0.65 ±
0.03; P < 0.01) (all P < 0.01). As compared with APACHE-II score (0.82 ± 0.02; P < 0.01), combination of CRP (0.83 ±
0.02; P < 0.01) or NT-proBNP (0.83 ± 0.02; P < 0.01) or both (0.84 ± 0.02; P < 0.01) with APACHE-II score did not
significantly increase C-index for predicting ICU mortality (all P > 0.05). However, addition of NT-proBNP to
APACHE-II score gave IDI of 6.6% (P = 0.003) and NRI of 16.6% (P = 0.007), addition of CRP to APACHE-II score
provided IDI of 5.6% (P = 0.026) and NRI of 12.1% (P = 0.023), and addition of both markers to APACHE-II score
yielded IDI of 7.5% (P = 0.002) and NRI of 17.9% (P = 0.002). In the cardiac subgroup (N = 213), NT-proBNP but not
CRP independently predicted ICU mortality and addition of NT-proBNP to APACHE-II score obviously increased
predictive ability (IDI = 10.2%, P = 0.018; NRI = 18.5%, P = 0.028). In the non-cardiac group (N = 363), CRP rather
than NT-proBNP was an independent predictor of ICU mortality.
Conclusions: In unselected medical ICU patients, NT-proBNP and CRP can serve as independent predictors of ICU
mortality and addition of NT-proBNP or CRP or both to APACHE-II score significantly improves the ability to predict
ICU mortality. NT-proBNP appears to be useful for predicting ICU outcomes in cardiac patients.
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N-terminal pro-brain natriuretic peptide (NT-proBNP)
is the inactive polypeptide of the pre-prohormone brain
natriuretic peptide (BNP). It is synthesized in the cardiac
myocytes in response to hemodynamic stress [1] or
inflammatory status [2]. Over the last decade, some stu-
dies have indicated that NT-proBNP testing greatly
increased the accuracy of the diagnosis of heart failure
in patients with dyspnea [3,4]. NT-proBNP can also
serve as a novel, independent predictor of prognosis in
cardiovascular patients [5-7] as well as in the general
population [8]. During the past few years, several studies
[9-16] have focused on the potential value of NT-
proBNP for prognosis of intensive care unit (ICU)
patients, but the performance of NT-proBNP to predict
adverse outcome in those patients is unimpressive [17].
First, the results of those studies have been conflicting.
Several studies have shown that NT-proBNP could serve
as an independent predictor of greater mortality in
patients with cardiogenic shock [9], septic shock [10],
severe sepsis [11], as well asi nn o n c a r d i a c[ 1 2 - 1 4 ]o r
unselected ICU patients [15], while another study [16]
demonstrated that NT-proBNP failed to predict short-
term mortality of ICU patients with hypoxic respiratory
failure. Second, most of these studies were rather small
and confounded by some factors, such as cardiovascular
disease, renal insufficiency, or inflammation [17],
although the prevalence of these conditions among
patients admitted to ICU is generally high.
C-reactive protein (CRP) is an extremely sensitive
objective marker of inflammation, tissue damage, and
infection. Its ability to provide predictive value of long-
term outcomes in ICU patients was just investigated in
limited studies [18-20]. There were less data about the
predictive value of CRP for short-term mortality [21,22].
In addition, although NT-proBNP and CRP have been
shown to be predictors of adverse outcomes in ICU
patients, the predictive value of the combination of both
for outcomes has not been investigated.
Currently, the Acute Physiology and Chronic Health
Evaluation II (APACHE-II) score is one of the most
common models used to evaluate ICU patients’ condi-
tion and predict their outcomes [23]. The additive abil-
ity of NT-proBNP and CRP to APACHE-II score to
predict ICU mortality has rarely been assessed. Tradi-
tionally, predictive models have been evaluated by
C- statistic, but this method has been criticized as being
insensitive in comparing models [24] and for having lit-
tle direct clinical relevance [25]. Several new methods
have recently been proposed to evaluate and compare
predictive risk models [26]. Calculation of net reclassifi-
cation improvement (NRI) and integrated discrimination
improvement (IDI) indices is now frequently being used
[27]. We hypothesized that the higher plasma level of
N T - p r o B N Pa n dC R Pw o u l db ei n d e p e n d e n t l ya s s o -
ciated with worse clinical outcomes in unselected ICU
patients. We, therefore, undertook a prospective, obser-
vational study to assess the prognostic value of
NT-proBNP, CRP or combination of both in a large
population of unselected medical ICU patients. We also
evaluated the ability of NT-proBNP and CRP additive to
APACHE-II score to predict ICU mortality by calcula-
tion of C-index, NRI and IDI indices.
Materials and methods
Participants
The prospective, observational trial was undertaken
between January 2009 and March 2010 at Xinhua Hospital
Affiliated to Shanghai Jiaotong University School of Medi-
cine. Medical patients were eligible for enrollment if they
needed to be transferred to ICU from emergency depart-
ment or other departments of our hospital (trauma and
surgical patients were not included). The decision to trans-
fer the patients into or out of ICU was made by at least
one critical care expert and one medical expert. Exclusion
criteria were age < 18 years and known pregnancy. Patients
who died within four hours of admission or were dis-
charged from the ICU within four hours of admission were
also excluded because data collection for those patients
was difficult. Patients were classified as cardiac or noncar-
diac subgroups according to their primary diagnosis.
Noncardiac was defined as a patient with a primary non-
cardiac diagnosis. Noncardiac did not preclude a secondary
cardiac disease, nor was a preexisting cardiac disease a
priori excluded. The study was approved by Shanghai
Jiaotong University Xinhua Hospital Ethics Committee
(XHEC2011-002) and in accordance with the Declaration
of Helsinki. Because this was an observational study and all
laboratory indices (including CRP and NT-pro-BNP)
observed were commonly measured for all patients in our
ICU department, the need for written informed consent
was waived by the review ethical review board.
Laboratory methods
The NT-proBNP level was determined using the Elecsys
Electro-chemo luminescent assay (Cobase 411 analyzer;
Roche Diagnostics; Mannheim, Germany). The analytical
range for NT-proBNP in the laboratory of our hospital
is 5 to 35,000 pg/mL. Readings > 35,000 pg/mL were
taken as 350,000 pg/mL. Reported total coefficient of
variation is 4.4% at mean concentration 248.9 ng/L and
3.91% at MC 5,449 ng/L, respectively, based on multi-
center calibrations of the automated Roche NT-proBNP
assay [28]. Serum creatinine (SCr) and albumin were
measured by the Hitachi 7600-120 (Hitachi, Tokyo,
Japan) analyzer. We calculated the estimated glomerular
filtration rate (eGFR) using the abbreviated Modification
of Diet in Renal Disease (MDRD) study equation: eGFR
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* (age) -0.203 *0.742 (if female), where SCr is serum
creatinine in mg/dL [29]. Serum CRP levels were mea-
sured using Quick Read CRP test kit (Orion Corpora-
tion, Orion Diagnostica, Espoo, Finland). Blood samples
were obtained from patients when they were admitted
to ICU for measurement of the indicators mentioned
previously.
Study outcomes
At baseline, demographic and clinical characteristics,
including the APACHE-II score (which can range from
0 to 71, with higher scores indicating more severe ill-
ness), were collected. Then the patients were followed
up during the ICU stay. The primary outcome of this
analysis was death in the ICU from any cause.
Statistical analysis
Continuous variables and categorical variables were pre-
sented as mean value ± SD and %, respectively. But
CRP, NT-proBNP and eGFR values were reported as
median (95% confidence interval) and then logarithmi-
cally normalized (presented as log-CRP, log-NT-proBNP
and log-eGFR, respectively) for statistical calculations
because they were skewed. Baseline characteristics
between survivals and non-survivals were compared
with unpaired Student’s t-test or Mann-Whitney test for
continuous variables and chi-square or Fisher’se x a c t
tests for categorical variables. Univariate logistic regres-
sion analyses were performed to examine the association
between mortality and each of the predictors separately.
We also conducted a forward stepwise multivariate
logistic regression to determine the independent predic-
tors of ICU mortality. A criterion of P <0 . 0 5f o re n t r y
and a P ≥ 0.10 for removal was imposed in this proce-
dure. Cox & Snell R Square and Nagelkerke R Square
were calculated for assessing the goodness of fit of the
models [30]. Odds ratios (ORs) for continuous variables
were described using standardized ORs, which were
associated with a one standard deviation change in the
variable. The receiver operating characteristic (ROC)
curve was used to examine the performance of variables
to predict ICU mortality. The curve represented a plot
of sensitivity vs 1-specificity. The area under the curve
(AUC, that is, C-index) was calculated from the ROC
curve. A statistically derived value, based on the Youden
index, maximizing the sum of the sensitivity and specifi-
city was used to define the optimal cut-off value [31].
ROC curve was also constructed for the combination of
two or three variables for predicting ICU mortality
according to the Mackinnon and Mulligan’sw e i g h t e d
sum rule [32]. The differences between AUC (C-index)
were tested by Hanley-McNeil methods in order to
examine whether the addition of one or both of the
biomarkers improved the discrimination of the model
[33]. The increased discriminative value of the biomar-
kers was further examined by calculation of NRI and
IDI indices described by Pencina et al. [27]. NRI is the
net increase versus decrease in risk categories among
case patients minus that among control participants. It
requires that there exist ap r i o r imeaningful risk cate-
gories (we used < 10%, 10% to 30%, and 30% to 50%,
and > 50% for the risk of ICU death) [26]. IDI is the dif-
ference in Yates slopes between models, in which the
Yates slope is the mean difference in predicted probabil-
ities between case patients and control participants [26].
A two-sided P-value of less than 0.05 was considered to
indicate statistical significance. All analyses were per-
formed with SPSS 13.0 software (SPSS Inc., Chicago,
Illinois, USA).
Results
Baseline characteristics
In all, 576 consecutive patients (55.7% male; mean age
71.16 ± 16.5 years) were screened for eligibility. Baseline
clinical and laboratory characteristics of the patients
were shown in Table 1. For the full population, the
median level of NT-proBNP, CRP and eGFR on admis-
sion was 2,922 (103 to 35,000.00) pg/ml, 39.8 (7.9 to
158.5) mg/L and 58.0 (6.5 to 150.0) mL/minute/1.73m
2,
respectively. The mean APACHE-Ⅱ score was 13.6 ± 7.1
points. The primary reasons for ICU admission were
cardiovascular disease and pulmonary disease. A total of
41.9% of the patients had accompanying infections.
A total of 131 (22.7%) patients died during the ICU hos-
pitalization. Non-survivors were older and in a more
severe condition as reflected by the higher APACHE-II
score, were more frequently septic or infectious, had
higher NT-proBNP, CRP, fasting plasma glucose, white
blood cell and heart rate, and had lower eGFR and
blood pressure on admission in the ICU as compared
with survivors (Table 1).
Predictors of ICU mortality
Univariate logistic regression analysis demonstrated that
those older, with higher level of NT-proBNP, CRP and
fasting plasma glucose, higher APACHE-II score and
lower eGFR had significantly greater hazard of death
(Table 2) (Because blood pressure, heart rate, white
blood cell counts and hemoglobin levels had been
included in APACHE-II score, they did not enter into
the analysis). When all the observed baseline variables
(Table 2) were included in a stepwise multiple logistic
model in which ICU mortality was the dependent vari-
able; only CRP, log-NT-proBNP, APACHE-II score and
fasting plasma glucose could independently predict pri-
mary outcome (P = 0.032, 0.011, 0.000 and 0.039,
receptively).
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mortality
To evaluate the value for the above independent vari-
ables to predict ICU mortality, ROC curves were drawn
(Figure 1). The AUC was calculated as 0.82 ± 0.02 (P <
0.01) for APACHE II score, 0.71 ± 0.03 (P <0 . 0 1 )f o r
NT-proBNP and 0.65 ± 0.03 (P <0 . 0 1 )f o rC R P .T h e
AUC of NT-proBNP or CRP was lower than that of
APACHE II score (all P < 0.01). The optimal cutoff
value of APACHE II score for predicting death was ≥
15, which gave sensitivity of 77.3% and specificity of
72.5%, and of NT-proBNP was ≥ 4,750 ng/ml, which
provided sensitivity of 69.5% and specificity of 68.8%.
The optimal cutoff value of CRP (≥ 27 mg/L) provided
sensitivity of 75.05% and specificity of 49.5%.
Table 1 Baseline clinical and laboratory characteristics of subjects
All Survivors Non-survivors P-value
Patients, No. 576 445 131 /
Male (%) 55.7 57.8 58.0 1.000
Age (years) 71.5 ± 16.5 70.5 ± 16.0 74.9 ± 14.3 0.004
Principal diagnosis leading to ICU admission (%)
Pulmonary disease 32.4 35.1 23.7 0.015
Cardiovascular disease 36.9 37.8 34.3 0.537
Neurologic disease 7.1 6.1 10.7 0.082
Digestive disease 5.6 6.1 3.8 0.391
Renal insufficiency 1.9 2.2 0.7 0.270
Poisoning 3.3 3.8 1.5 0.470
Infectious disease/sepsis 5.6 2.7 15.2 < 0.001
Other 7.1 6.3 9.9 0.175
Hypertension (%) 58.0 58.7 55.7 0.548
Diabetes mellitus (%) 25.9 24.7 29.8 0.257
Accompanying infection (%) 41.9 42.9 45.0 0.035
Systolic pressure (mmHg) 124.9 ± 22.4 127.4 ± 21.2 116.8 ± 24.7 < 0.001
Diastolic pressure (mmHg) 68.0 ± 12.2 69.3 ± 11.6 63.9 ± 13.3 < 0.001
Heart rate (bpm) 91.0 ± 20.5 89.2 ± 19.1 97.3 ± 24.0 < 0.001
Fasting plasma glucose (mmol/L) 11.4 ± 6.3 7.12 ± 2.9 8.5 ± 4.3 < 0.001
White blood cell (10
9/L) 7.4 ± 3.4 10.8 ± 5.6 13.5 ± 7.9 < 0.001
Hemoglobin (g/L) 116.3 ± 25.4 118.7 ± 24.0 108.1 ± 28.1 < 0.001
eGFR(mL/min/1.73 m
2) 58.0 (6.5 to 150.0) 62.6 (14.5 to 30.2) 34.8 (8.2 to 108.7) < 0.001
APACHE-II score (points) 13.6 ± 7.1 11.7 ± 5.6 19.9 ± 7.5 < 0.001
NT-proBNP (ng/ml) 2,922 (103 to 35,000) 5,996 (6 to 35,000) 12,726 (59 to 35,000) < 0.001
CRP(mg/L) 39.8 (7.9 to 158.5) 56.7 (1.0 to 160.1) 85.9 (6.0 to 160.2) < 0.001
APACHE II score, Acute Physiology and Chronic Health Evaluation II score; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; NT-proBNP,
N-7terminal pro-brain natriuretic peptide.
Table 2 Univariate odds ratios of variables for predicting
ICU mortality
Predictor Odds ratio 95% CI P
Age 1.430 1.154 to 1.772 0.001
Sex / / 0.992
Log-NT-proBNP 2.202 1.728 to 2.807 < 0.001
Fasting plasma glucose 1.445 1.201 to 1.741 < 0.001
APACHE-II score 4.359 3.301 to 5.756 < 0.001
Log-eGFR 0.362 0.276 to 0.476 < 0.001
Log-CRP 1.768 1.439 to 2.173 < 0.001
Odds ratios for continuous variables shown as standardized odds ratios (OR
per 1 SD). Log-variable is the logarithm of the variable. APACHE II score, Acute
Physiology and Chronic Health Evaluation II score; CRP, C-reactive protein; NT-
proBNP, eGFR, estimated glomerular filtration rate; N-terminal pro-brain
natriuretic peptide.
Figure 1 ROC curves for APACHE II score, CRP and NT-proBNP
in prediction of ICU mortality. The area under the ROC curve
(AUC) of NT-proBNP were larger than that of CRP or NT-proBNP (all
P < 0.01).
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T of u r t h e rc l a r i f yw h e t h e rC R Po rN T - p r o B N Po rt h e
combination of both had an additive power with
APACHE-II score for predicting ICU mortality, we com-
bined one or two biomarkers with the APACHE-II score
to construct new ROC curves (Figure 2). As compared
with the APACHE-II score (AUC 0.82 ± 0.02), combina-
tion of CRP (AUC 0.83 ± 0.02) or NT-proBNP (AUC
0.83 ± 0.02) or both (AUC 0.84 ± 0.02) with the
APACHE-II score did not significantly increase AUC for
predicting ICU mortality (P = 0.74, 0.74 and 0.47, respec-
tively). The combination of CRP and NT-proBNP (AUC
0.72 ± 0.03) was inferior to APACHE-II score for predict-
ing ICU mortality (P < 0.01). In addition, the forward
stepwise logistic regression showed that the addition of
NT-proBNP or both biomarkers to the APACHE-II score
slightly increased the ability of the model to predict ICU
mortality. The Cox & Snell R Square and Nagelkerke R
Square in the model were slightly increased. (Table 3)
However, when using new statistical analysis methods
(NRI and IDI indices) which are more sensitive than the
above statistics, we found that the addition of NT-
proBNP or CRP or both to the APACHE-II score signifi-
cantly improved the ability to predict the outcome (Table
4). The addition of NT-proBNP to he APACHE-II score
gave an IDI of 6.6% (P = 0.003) and NRI of 16.6% (P =
0.007). The addition of CRP to the APACHE-II score
provided an IDI of 5.6% (P = 0.026) and NRI of 12.1% (P
= 0.023), and the addition of both markers to the
APACHE-II score yielded an IDI of 7.5% (P =0 . 0 0 2 )a n d
NRI of 17.9% (P = 0.002).
Subgroups analysis
In the non-cardiac subgroup (N = 363), the AUC with
respect to the prediction of ICU mortality was 0.82 ±
0.03 (P < 0.01) for the APACHE II score, 0.70 ± 0.03 (P
< 0.01) for NT-proBNP and 0.64 ± 0.04 (P < 0.01) for
CRP. The AUC of the APACHE II score was larger than
that of NT-proBNP or CRP (P < 0.01). Multiple logistic
regression showed that CRP and APACHE-II scores
were independent predictors of ICU mortality (all P <
0 . 0 1 ;T a b l e5 ) .H o w e v e r ,t h ea d d i t i o no fC R Pt ot h e
APACHE-II score in the model just slightly increased
Cox & Snell R Square and Nagelkerke R Square (Table
5), and did not improve the AUC (0. 82 ± 0.03 vs 0.83
±0 . 0 3 ,P = 0.82). The IDI (2.89%, Z = 0.91, P = 0.33)
and NRI (6.36%, Z = 1.15, P = 0.25) were also not statis-
tically significant. In the cardiac subgroup (N = 213), the
AUC with respect to the prediction of ICU mortality
was calculated as 0.81 ± 0.03 (P <0 . 0 1 )f o rt h e
APACHE II score, 0.77 ± 0.04 (P < 0.01) for NT-
proBNP and 0.69 ± 0.04 (P <0 . 0 1 )f o rC R P .T h eA U C
of the APACHE-II score was not different from that of
NT-proBNP (P = 0.42), while the AUC of both was
lager than that of CRP (P < 0.01). Multiple logistic
regression analysis demonstrated that NT-proBNP and
the APACHE-II score were independent predictors of
ICU mortality (all P < 0.01; Table 6). The addition of
NT-proBNP to the APACHE-II score can obviously
increase Cox & Snell R Square and Nagelkerke R Square
(Table 6). Although the AUC increased (0.82 ± 0.03 vs
0.86 ± 0.03, P = 0.35) insignificantly, the IDI (10.2%, Z
=2 . 5 5 ,P = 0.018) and NRI (18.5%, Z = 2.20, P =0 . 0 2 8 )
were statistically significant.
Discussion
In this large scale study of 576 unselected medical ICU
patients, we found that NT-proBNP and CRP indepen-
dently predicted ICU mortality even after adjustment for
the APACHE II score and multiple potential confoun-
ders including eGFR, age, and so on. Although the pre-
dictive ability was lower as compared with the APACHE
II score, the addition of CRP or NT-proBNP or both to
the APACHE II score could significantly improve the
ability to predict ICU mortality, as demonstrated by IDI
and NRI indices. NT-proBNP appeared to be more use-
ful for predicting ICU outcomes in cardiac patients. To
our knowledge, this is the first large-scale study to eval-
uate the ability of NT-proBNP and CRP added to the
APACHE-II score to predict ICU mortality, especially
using the new statistics method, that is, the NRI and
IDI indices.
BNP and NT-proBNP have become promising bio-
markers recently. They have been used as tools for risk
stratification in cardiac patients [3-7], the general popu-
lation [8] and ICU patients [9-18]. Most of the studies
investigating the predictive value of NT-proBNP in ICU
patients were confounded by some factors, such as renal
insufficiency or inflammation. Our study showed that
Figure 2 ROC curves for combination of two or three variables
among CRP, NT-proBNP and APACHE-II score. Combination of
CRP or NT-proBNP or both with APACHE-II score did not
significantly increase AUC with regard to perdition of ICU mortality
(all P > 0.05). Combination of CRP and NT-proBNP was inferior to
APACHE-II score alone for predicting ICU mortality (P < 0.01).
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unselected patients even after adjustment for the
APACHE II score and other potential confounders,
including age, renal insufficiency (eGFR), and inflamma-
tion (CRP). However, the ability of NT-proBNP to pre-
dict ICU mortality was lower than that of the APACHE
II score (AUC: 0.82 ± 0.02 vs 0.71 ± 0.03, P < 0.01; OR:
1.454 vs 3.532). The C statistic is the most commonly
used method of determining model discrimination. In
this method, we found that the addition of one or both
the biomarkers to the APACHE II score did not signifi-
cantly improve the predictive ability (AUC). However,
the sole reliance on the C-statistic for the evaluation of
predictors has been questioned, because very large inde-
pendent associations of a new marker with the outcome
are required to result in a significant increase in the C
statistic [24,25]. In the present study, we also used a
more sensitive test of improvement in model discrimi-
nation [27]. We found that the addition of NT-proBNP
to the APACHE II score significantly increased the abil-
ity to predict ICU mortality as demonstrated by the IDI
(6.6%, P = 0.003) and NRI (16.6%, P = 0.007) indices.
NT-proBNP was not an independent predictor of ICU
mortality in the non-cardiac subgroup after adjustment
for APACHE II score and CRP. Kotanidou et al.[ 1 3 ]
found that NT-proBNP predicted mortality indepen-
dently after the adjusted APACHE II score and some
inflammatory cytokines levels in non-cardiac ICU
patients. But they used TNF-a, IL-6, and IL-10 rather
than CRP and enrolled many surgical and multiple
trauma cases. In the cardiac subgroup, NT-proBNP
independently predicted ICU mortality while the AUC
of the APACHE II score was not different from that of
NT-proBNP (0.81 ± 0.03 vs 0.77 ± 0.04; P > 0.05). The
addition of NT-proBNP to the APACHE-II score can
obviously increase predictive ability (IDI = 10.2%, P =
0.018; NRI = 18.5%, P = 0.028). Therefore, although
NT-proBNP could predict ICU mortality in unselected
medical patents, it appeared to be more useful in cardiac
patients than in non-cardiac patients.
LV wall tension is regarded as the primary mechanism
regulating NT-proBNP secretion [1]. Other hemody-
namic factors that may contribute to NT-proBNP secre-
tion include left ventricular diastolic dysfunction and
right ventricular overload and dysfunction [10,34].
Other mechanisms proposed to account for high
NT-proBNP values include renal dysfunction [35] and
inflammatory status [36,37]. Therefore, patients with
high NT-proBNP may have cardiac dysfunction, renal
dysfunction or inflammatory status. All of these factors
have shown to be a frequent and important factors in
determining the outcome of critically ill patients
[18-21,38]. This is the reason why NT-proBNP can be
used as a predictor of outcomes in ICU patients.
CRP has long been considered to be a distinct and
sensitive biomarker of inflammation, tissue damage, and
infection. Some studies also suggest that CRP may be an
indicator of organ failure [22]. Only a few studies have
tested its value for predicting outcome in ICU patients
[18-22]. However, most of these studies observed the
post-ICU outcomes but not ICU mortality. NT-proBNP
was not included in their analyses, either. One previous
study showed no predictive value of CRP for in-hospital
mortality, even in univariate analysis [21]. The scope of
the study was rather small (N = 103) and, thus, the sta-
tistical power was less than that of our study. Moreover,
Table 4 Independent predictors of ICU mortality by multivariate logistic regression in all patients (appending models
summary)
OR OR-st P -2 Log likelihood Cox & Snell R Square Nagelkerke R Square
Model I APACHE-II score 1.225 4.359 0.000 467.269 0.215 0.328
Model II Log-NT-proBNP 1.633 1.454 0.008 458.360 0.228 0.346
APACHE-II score 1.196 3.532 0.000
Model III Log-CRP 1.778 1.355 0.017
Log-NT-proBNP 1.628 1.448 0.011 452.586 0.236 0.358
APACHE-II score 1.183 3.225 0.000
APACHE II score, Acute Physiology and Chronic Health Evaluation II score; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; OR, odds ratio; OR-st,
standardized Odds ratios (OR per 1 SD); NT-proBNP, N-terminal pro-brain natriuretic peptide.
Table 3 NRI and IDI for assessing improvement in model performance after adding biomarkers to APACHE-II score
NRI Z value for NRI P-value for NRI IDI Z value for NRI P-value for NRI
APACHE-II score + log(NT-proBNP) 16.6% 2.982 0.003 6.6% 2.680 0.007
APACHE-II score + log(CRP) 12.1% 2.216 0.026 5.6% 2.267 0.023
APACHE-II score + log(NT-proBNP) +log(CRP) 17.9% 3.042 0.002 7.5% 3.036 0.002
APACHE II score, Acute Physiology and Chronic Health Evaluation II score; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IDI, integrated
discrimination improvement; NRI, Net reclassification improvement; N-terminal pro-brain natriuretic peptide; NT-proBNP
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Page 6 of 9the endpoint of the previous study was in-hospital mor-
tality but not ICU mortality. The present study revealed
that CRP was also an independent predictor of ICU
mortality in unselected patients or non-cardiac patients.
Although the C-statistic showed the addition of CRP to
the APACHE-II score in prediction of ICU mortality did
not significantly improve the predictive ability, NRI
(12.1%, P = 0.026) and IDI (5.6%, P = 0.023) were statis-
tically significant.
Several limitations of our study should be mentioned.
First, neither echocardiography was performed nor cardiac
function assessed in the present study. The division of sub-
groups was according to primary admission cause. Thus
patients in the non-cardiac group may also have cardiac
disease and cardiac dysfunction. However, patients with
cardiac diseases as the primary principal diagnosis leading
to ICU admission must have cardiac diseases. The statisti-
cal conclusion drawn from the cardiac group was appropri-
ate. Second, this was a single-center study, and participants
did not include surgery and trauma patients. The value for
NT-proBNP in prediction of adverse outcome would be a
bit different if the population was different. At last, a lim-
itation of the net reclassification improvement and other
reclassification measures is that they depend on the parti-
cular categories used [26]. We had used < 10%, 10% to
30%, and 30% to 50%, and > 50% for the risk of ICU death
as risk categories. But there are still no well-recognized risk
categories now. If the risk categories used had been differ-
ent, the NRI would be a bit different.
Conclusions
In this large-scale study of unselected ICU patients, we
confirmed that NT-proBNP and CRP can serve as mod-
erate independent predictors of ICU mortality. Although
the predictive ability was lower compared with the
APACHE II score, but the addition of CRP or
NT-proBNP or both to the APACHE II score could sig-
nificantly improve the ability to predict ICU mortality,
as demonstrated by IDI and NRI indices. NT-proBNP
appeared to be more useful for predicting ICU out-
comes in cardiac patients.
Key messages
● NT-proBNP and CRP independently predicted ICU
mortality even after adjustment for the APACHE II
score and multiple potential confounders.
● The ability of NT-proBNP and CRP to predict
ICU mortality was lower compared with the
APACHE II score.
● The addition of CRP or NT-proBNP or both to
the APACHE II score could significantly improve
the ability to predict ICU mortality as demonstrated
by IDI and NRI indices.
● N T - p r o B N Pa p p e a r e dt ob em o r eu s e f u lf o rp r e -
dicting ICU outcomes in cardiac patients.
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Table 6 Independent predictors of ICU mortality by multivariate logistic regression in cardiac patients (appending
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OR OR-st P -2 Log likelihood Cox & Snell R Square Nagelkerke R Square
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APACHE-II score 1.226 3.618 0.000
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terminal pro-brain natriuretic peptide; OR, odds ratio; OR-st, standardized Odds ratios (OR per 1 SD).
Table 5 Independent predictors of ICU mortality by multivariate logistic regression in non-cardiac patients (appending
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OR OR-st P -2 Log likelihood Cox & Snell R Square Nagelkerke R Square
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Model II Log-CRP 2.056 1.451 0.002 290.175 0.242 0.365
APACHE-II score 1.198 3.781 0.000
OR, odds ratio; OR-st, standardized Odds ratios (OR per 1 SD); APACHE II score, Acute Physiology and Chronic Health Evaluation II score; eGFR, estimated
glomerular filtration rate; CRP, C-reactive protein; NT-proBNP, N-terminal pro-brain natriuretic peptide.
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